Skip to main content
XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
1.600
-0.040 (-2.44%)
Nov 13, 2026, 4:00 PM EST - Market closed

XTL Biopharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-1.47-1.47-0.78-0.77-0.88-1.03
Net Income
-6.97-6.97-1.03-1.78-1.350.44
Earnings Per Share
-0.01-0.01-0.00-0.00-0.000.00
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.080.081.142.013.726.13
Total Debt
--0.14---
Net Cash (Debt)
0.080.081.012.013.726.13
Net Cash Growth
-95.58%-92.44%-49.90%-46.09%-39.27%1.41%
Net Cash Per Share
0.000.000.000.000.010.01

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1.03-1.03-1.62-0.71-0.9-1.05
Capital Expenditures
---0.05---
Free Cash Flow
-1.03-1.03-1.67-0.71-0.9-1.05
Free Cash Flow Growth
------

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----34.41